Special Issue "Ovarian Cancer and Female Health"

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Behavior, Chronic Disease and Health Promotion".

Deadline for manuscript submissions: 30 September 2021.

Special Issue Editors

Dr. Evgenia Halkia
E-Mail Website
Guest Editor
Peritoneal Surface Malignancy Program and HIPEC, at the 4thSurgical Department at “ATTIKON” University Hospital and Medical School, National and Kapodistrian University of Athens, Rimini 1, Chaidari, Greece.
Interests: cytoreductive surgery; ovarian cancer; surgery; peritoneal metastases
Prof. Dr. Jesus Esquivel
E-Mail Website
Guest Editor
Department of surgical oncology, Frederick Memorial Hospital, 21701 Frederick, MD, USA.
Interests: surgical oncology; cytoreductive surgery; HIPEC

Special Issue Information

Dear Colleagues,

Ovarian Cancer is the deadliest of all gynecologic malignancies, despite significant advances in surgical techniques, chemotherapeutic options, and supportive care during the last few decades.

In the early stages, it often remains asymptomatic because of the anatomic location of the ovaries deep in the pelvis. Standard management of patients with tumor localized to the ovary(ies) includes comprehensive surgical staging in order to provide guidance for a subsequent need for adjuvant treatment. The extent of residual disease after radical surgical cytoreduction represents a significant predictor for progression-free and overall survival.

Hyperthermic intraperitoneal chemotherapy has shown significant survival benefits over standard systemic intravenous chemotherapy in metastatic disease that has been optimally debulked, in the primary, interval, or recurrent setting.

This invitation aims to reach out to surgical and gynecologic oncologists treating patients with cytoreductive surgery, interval debulking, systemic (neoadjuvant/adjuvant), and hyperthermic intraperitoneal chemotherapy, as well as molecular targeted and immunologically active agents.

Subjects such as fertility-sparing surgery, multidisciplinary surgical approaches, perioperative staging and re-staging systems, patient selection processes for active treatment options or palliation, peritonectomy procedures, indications for lymph node resection, management of recurrent disease, molecular targets, immunotherapy, genetic counseling,  and the use of hyperthermic intraperitoneal chemotherapy (HIPEC) are kindly requested for submission.

The scope of this Thematic Issue is to bring attention to recent advances in the management algorithm of ovarian cancer patients during the different stages of the disease, in order to promote the conversion of a lethal disease into a chronic disease.

Dr. Evgenia Halkia
Prof. Dr. Jesus Esquivel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • ovarian cancer
  • fertility-sparing surgery
  • peritoneal metastases
  • cytoreductive surgery
  • debulking surgery
  • systemic chemotherapy
  • ovarian cancer targeted therapy
  • hyperthermic intraperitoneal chemotherapy
  • peritonectomy procedures
  • peritoneal carcinomatosis
  • adnexal mass
  • hepatic metastases in ovarian cancer
  • ovarian cancer peritoneal carcinomatosis
  • malignant ascites

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3′-Untranslated Region of DLC1
Int. J. Environ. Res. Public Health 2021, 18(11), 5741; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18115741 - 27 May 2021
Viewed by 462
High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer with highly metastatic properties. A small non-coding RNA, microRNA (miRNA) was discovered to be a major regulator in many types of cancers through binding at the 3′-untranslated region (3′UTR), leading to degradation [...] Read more.
High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer with highly metastatic properties. A small non-coding RNA, microRNA (miRNA) was discovered to be a major regulator in many types of cancers through binding at the 3′-untranslated region (3′UTR), leading to degradation of the mRNA. In this study, we sought to investigate the underlying mechanisms involved in the dysregulation of miR-200c-3p in HGSC progression and metastasis. We identified the upregulation of miR-200c-3p expression in different stages of HGSC clinical samples and the downregulation of the tumor suppressor gene, Deleted in Liver Cancer 1 (DLC1), expression. Over expression of miR-200c-3p in HGSC cell lines downregulated DLC1 but upregulated the epithelial marker, E-cadherin (CDH1). Based on in silico analysis, two putative binding sites were found within the 3′UTR of DLC1, and we confirmed the direct binding of miR-200c-3p to the target binding motif at position 1488–1495 bp of 3′UTR of DLC1 by luciferase reporter assay in a SKOV3 cell line co-transfected with vectors and miR-200c-3p mimic. These data showed that miR-200c-3p regulated the progression of HGSC by regulating DLC1 expression post-transcription and can be considered as a promising target for therapeutic purposes. Full article
(This article belongs to the Special Issue Ovarian Cancer and Female Health)
Show Figures

Figure 1

Back to TopTop